Premium
Risankizumab for the treatment of plaque psoriasis in adults
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1812
Subject(s) - medicine , plaque psoriasis , psoriasis , dermatology
Risankizumab (Skyrizi) is an anti‐IL‐23 monoclonal antibody therapy for the treatment of plaque psoriasis in adults. This article discusses its clinical trial efficacy, adverse effects and place in therapy.